CNS Pharmaceuticals initiated with a Buy at Alliance Global Partners

Alliance Global Partners initiated coverage of CNS Pharmaceuticals (CNSP) with a Buy rating and $4 price target CNS is a clinical-stage pharmaceutical company focused on developing drug candidates targeting central nervous system malignancies, with a primary focus on glioblastoma multiforme, or brain cancer, the analyst tells investors in a research note. The firm believes the opportunity for the company could be significant should Berubicin show positive data in the first half of 2025.